On Friday, the U.S. Food and Drug Administration (FDA) will hold its first public hearing about regulations regarding legal cannabis and cannabidiol (CBD).
Among some 140 registered speakers scheduled to provide comment during the daylong event, stakeholders in the hemp and CBD industries say that the goal of the meeting and subsequent hearings will be to determine the extent to which the agency should regulate cannabis and CBD as tightly controlled pharmaceutical products or as less restricted nutritional supplements.
Rather than any immediate, concrete results from the hearing, stakeholders will seek to recognize trends and consensus from among those assembled.
“Effectively, the FDA is asking questions first about cannabis-derived compounds rather than marijuana versus hemp,” explained Garrett Graff, managing attorney with Denver-based Hoban Law Group, who is among the scheduled speakers. “The hearing is framed around cannabis generally, not marijuana or hemp specifically.”